Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taletrectinib in CDH1-mutated Invasive Lobular Breast Cancer
NCT06214793Phase 2Suspended
- Sponsor
- Kruse Comms
- Start
- Oct 2026
- Primary completion
- Jan 2030
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of taletrectinib in breast cancer, sponsored by Kruse Comms. Primary endpoint: Objective Response Rate at 24 weeks. Started Oct 2026; status: suspended.
02
Drugs
taletrectinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06214793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06214793.